Jerome A Zack

List of Publications by Year
in descending order

73 papers	8,921 citations	81900 39 h-index	74163 75 g-index
76 all docs	76 docs citations	76 times ranked	8883 citing authors

#	Article	IF	Citations
1	Latency reversal plus natural killer cells diminish HIV reservoir in vivo. Nature Communications, 2022, 13, 121.	12.8	36
2	Stem cellâ€“derived CAR T cells traffic to HIV reservoirs in macaques. JCI Insight, 2021, 6, .	5.0	19
3	Robust CAR-T memory formation and function via hematopoietic stem cell delivery. PLoS Pathogens, 2021, 17, e1009404.	4.7	19
4	Pharmacological Activation of Non-canonical NF-ÎºB Signaling Activates Latent HIV-1 Reservoirs InÂVivo. Cell Reports Medicine, 2020, 1, 100037.	6.5	26
5	Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 10688-10698.	7.1	34
6	Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy. Nature Communications, 2020, 11, 1879.	12.8	29
7	Tracking HIV Rebound following Latency Reversal Using Barcoded HIV. Cell Reports Medicine, 2020, 1, 100162.	6.5	11
8	Essential Role of Human T Cell Leukemia Virus Type 1 orf-I in Lethal Proliferation of CD4 ⁺ Cells in Humanized Mice. Journal of Virology, 2019, 93, .	3.4	15
9	Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell Stem Cell, 2019, 25, 542-557.e9.	11.1	48
10	Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1 ⁺ and TIGIT ⁺ CD4 T Cells. Journal of Virology, 2019, 93, .	3.4	21
11	HIV cure strategies: a complex approach for a complicated viral reservoir?. Future Virology, 2019, 14, 5-8.	1.8	11
12	Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology, 2018, 520, 83-93.	2.4	33
13	Humanized Mouse Models for Human Immunodeficiency Virus Infection. Annual Review of Virology, 2017, 4, 393-412.	6.7	65
14	New approaches for the enhancement of chimeric antigen receptors for the treatment of HIV. Translational Research, 2017, 187, 83-92.	5.0	13
15	In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication. PLoS Pathogens, 2017, 13, e1006575.	4.7	73
16	Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS. PLoS Pathogens, 2017, 13, e1006753.	4.7	91
17	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	30.7	395
18	Engineering HIV-Specific Immunity with Chimeric Antigen Receptors. AIDS Patient Care and STDs, 2016, 30, 556-561.	2.5	14

#	Article	IF	Citations
19	HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies. Journal of Virology, 2016, 90, 6999-7006.	3.4	80
20	Medial HOXA genes demarcate haematopoietic stem cell fate during human development. Nature Cell Biology, 2016, 18, 595-606.	10.3	81
21	Propagating Humanized BLT Mice for the Study of Human Immunology and Immunotherapy. Stem Cells and Development, 2016, 25, 1863-1873.	2.1	37
22	Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model. Journal of Visualized Experiments, 2016, , .	0.3	12
23	A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells. Cell Stem Cell, 2016, 18, 533-540.	11.1	307
24	Cocaine-mediated impact on HIV infection in humanized BLT mice. Scientific Reports, 2015, 5, 10010.	3.3	16
25	Disruption of Type I Interferon Induction by HIV Infection of T Cells. PLoS ONE, 2015, 10, e0137951.	2.5	18
26	Cocaine exposure impairs multilineage hematopoiesis of human hematopoietic progenitor cells mediated by the sigma-1 receptor. Scientific Reports, 2015, 5, 8670.	3.3	5
27	HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells. Molecular Therapy, 2015, 23, 1358-1367.	8.2	111
28	Double Trouble: HIV Latency and CTL Escape. Cell Host and Microbe, 2015, 17, 141-142.	11.0	15
29	Lymphoid Regeneration from Gene-Corrected SCID-X1 Subject-Derived iPSCs. Cell Stem Cell, 2015, 16, 367-372.	11.1	68
30	Studies of retroviral infection in humanized mice. Virology, 2015, 479-480, 297-309.	2.4	33
31	RNAi-Mediated CCR5 Knockdown Provides HIV-1 Resistance to Memory T Cells in Humanized BLT Mice. Molecular Therapy - Nucleic Acids, 2015, 4, e227.	5.1	28
32	Experimental Approaches for Eliminating Latent HIV. Forum on Immunopathological Diseases and Therapeutics, 2015, 6, 91-99.	0.1	16
33	CD4 Ligation on Human Blood Monocytes Triggers Macrophage Differentiation and Enhances HIV Infection. Journal of Virology, 2014, 88, 9934-9946.	3.4	63
34	Bioengineered Vaults: Self-Assembling Protein Shellâ€“Lipophilic Core Nanoparticles for Drug Delivery. ACS Nano, 2014, 8, 7723-7732.	14.6	54
35	Neutralizing the HIV Reservoir. Cell, 2014, 158, 971-972.	28.9	12
36	HIV restriction in quiescent CD4+T cells. Retrovirology, 2013, 10, 37.	2.0	45

#	Article	IF	Citations
37	HIV/AIDS eradication. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4003-4010.	2.2	40
38	Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11698-11703.	7.1	130
39	Introduction of Exogenous T-cell Receptors Into Human Hematopoietic Progenitors Results in Exclusion of Endogenous T-cell Receptor Expression. Molecular Therapy, 2013, 21, 1055-1063.	8.2	36
40	Interferon-Inducible Cholesterol-25-Hydroxylase Broadly Inhibits Viral Entry by Production of 25-Hydroxycholesterol. Immunity, 2013, 38, 92-105.	14.3	554
41	HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood, 2013, 122, 2195-2204.	1.4	47
42	In Vivo Suppression of HIV by Antigen Specific T Cells Derived from Engineered Hematopoietic Stem Cells. PLoS Pathogens, 2012, 8, e1002649.	4.7	74
43	HIV Latency in the Humanized BLT Mouse. Journal of Virology, 2012, 86, 339-347.	3.4	106
44	Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nature Chemistry, 2012, 4, 705-710.	13.6	152
45	HIV latency is influenced by regions of the viral genome outside of the long terminal repeats and regulatory genes. Virology, 2011, 417, 394-399.	2.4	8
46	Activation of Latent HIV Using Drug-Loaded Nanoparticles. PLoS ONE, 2011, 6, e18270.	2.5	80
47	A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood, 2010, 115, 1534-1544.	1.4	132
48	Establishment and maintenance of HIV latency: model systems and opportunities for intervention. Future Virology, 2010, 5, 97-109.	1.8	26
49	Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nature Medicine, 2009, 15, 285-292.	30.7	259
50	Eradication of HIV: current challenges and new directions. Journal of Antimicrobial Chemotherapy, 2008, 63, 7-10.	3.0	55
51	Human Immunodeficiency Virus Bearing a Disrupted Central DNA Flap Is Pathogenic In Vivo. Journal of Virology, 2007, 81, 6146-6150.	3.4	26
52	Primary Cell Model for Activation-Inducible Human Immunodeficiency Virus. Journal of Virology, 2007, 81, 7424-7434.	3.4	31
53	Rapid Expression of Human Immunodeficiency Virus following Activation of Latently Infected Cells. Journal of Virology, 2006, 80, 1599-1603.	3.4	28
54	Prostratin and Bortezomib are Novel Inducers of Latent Kaposi'S Sarcoma-Associated Herpesvirus. Antiviral Therapy, 2005, 10, 745-751.	1.0	34

#	Article	IF	Citations
55	The CCR5 and CXCR4 Coreceptorsâ€"Central to Understanding the Transmission and Pathogenesis of Human Immunodeficiency Virus Type 1 Infection. AIDS Research and Human Retroviruses, 2004, 20, 111-126.	1.1	441
56	Molecular Characterization, Reactivation, and Depletion of Latent HIV. Immunity, 2003, 19, 413-423.	14.3	184
57	HIV Type 1 Infection Alters Cytokine mRNA Expression in Thymus. AIDS Research and Human Retroviruses, 2003, 19, 1-12.	1.1	14
58	Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12955-12960.	7.1	97
59	Interleukin-7 Induces Expression of Latent Human Immunodeficiency Virus Type 1 with Minimal Effects on T-Cell Phenotype. Journal of Virology, 2002, 76, 13077-13082.	3.4	170
60	Effects of Prostratin on T-Cell Activation and Human Immunodeficiency Virus Latency. Journal of Virology, 2002, 76, 8118-8123.	3.4	205
61	Effect of Latent Human Immunodeficiency Virus Infection on Cell Surface Phenotype. Journal of Virology, 2002, 76, 1673-1681.	3.4	31
62	Negative Regulation of Neural Stem/Progenitor Cell Proliferation by the Pten Tumor Suppressor Gene in Vivo. Science, 2001, 294, 2186-2189.	12.6	761
63	Upregulation of CD4 on CD8+ T cells: CD4dimCD8bright T cells constitute an activated phenotype of CD8+ T cells. Immunology, 2001, 103, 270-280.	4.4	100
64	Generation of HIV latency during thymopoiesis. Nature Medicine, 2001, 7, 459-464.	30.7	165
65	Functional Reconstitution of Thymopoiesis after Human Immunodeficiency Virus Infection. Journal of Virology, 2000, 74, 2943-2948.	3.4	12
66	Human Immunodeficiency Virus Type 1-Induced Hematopoietic Inhibition Is Independent of Productive Infection of Progenitor Cells In Vivo. Journal of Virology, 1999, 73, 9089-9097.	3.4	60
67	Human Immunodeficiency Virus Inhibits Multilineage Hematopoiesis In Vivo. Journal of Virology, 1998, 72, 5121-5127.	3.4	67
68	Regions of Human Immunodeficiency Virus Type 1 nef Required for Function In Vivo. Journal of Virology, 1998, 72, 7032-7039.	3.4	56
69	Preparation and Maintenance of SCID-hu Mice for HIV Research. Methods, 1997, 12, 343-347.	3.8	11
70	Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy. Nature Medicine, 1997, 3, 1102-1109.	30.7	75
71	The SCID-hu mouse as a model for HIV-1 infection. Nature, 1993, 363, 732-736.	27.8	327
72	HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature, 1990, 348, 69-73.	27.8	703

#	Article	IF	Citations
73	HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell, 1990, 61, 213-222.	28.9	1,657